taurine has been researched along with Liver Dysfunction in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of oral taurine supplementation on frequency, duration, and intensity of muscle cramps in patients with chronic liver disease." | 9.27 | Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease. ( Allman-Farinelli, M; Carey, S; Cvejic, E; McCaughan, GW; Shackel, NA; Strasser, SI; Vidot, H, 2018) |
| "Ursodeoxycholic acid administration has been reported to improve cholestasis and inflammatory activity in primary biliary cirrhosis and, in an uncontrolled study, also in young adults with cystic fibrosis (CF) and chronic cholestasis." | 9.07 | Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. ( Angelico, M; Antonelli, M; Bertasi, S; De Santis, A; Diamanti, S; Goffredo, F; Martino, F; Merli, M; Quattrucci, S; Servi, R, 1994) |
| "This study was undertaken to clarify the effects of taurine on liver injury in rats with severe acute pancreatitis (SAP)." | 7.78 | Taurine attenuates liver injury by downregulating phosphorylated p38 MAPK of Kupffer cells in rats with severe acute pancreatitis. ( Chen, Y; Gong, J; Huang, Q; Li, J; Liu, Z; Wei, S; You, H, 2012) |
| "NorUDCA (24-norursodeoxycholic acid), the C₂₃-homolog of ursodeoxycholic acid (UDCA), showed remarkable therapeutic effects in cholestatic Mdr2 (Abcb4) (multidrug resistance protein 2/ATP-binding cassette b4) knockout mice with sclerosing/fibrosing cholangitis." | 7.76 | Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. ( Beuers, U; Denk, GU; Ferdinandusse, S; Fickert, P; Fuchsbichler, A; Hofmann, AF; Invernizzi, P; Kulik, W; Maitz, S; Rust, C; Trauner, M; Wimmer, R, 2010) |
| "The hydrophilic bile acid ursodeoxycholic acid (UDCA) has recently been shown to improve indexes of liver function in adult patients with various liver diseases." | 7.68 | Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. ( Colombo, C; Crosignani, A; Curcio, L; Giunta, A; Podda, M; Roda, A; Ronchi, M; Setchell, KD, 1990) |
| "Treatment with taurine was followed by a significant increase in serum prealbumin levels (P = ." | 6.68 | Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. ( Battezzati, PM; Bettinardi, N; Colombo, C; Giunta, A; Podda, M, 1996) |
| "Taurine treatment seems to be a useful agent for CYP2E1-related liver diseases with predominant damages in the PC region." | 6.50 | Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine. ( Matsuzaki, Y; Miyazaki, T, 2014) |
| "To investigate the effect of oral taurine supplementation on frequency, duration, and intensity of muscle cramps in patients with chronic liver disease." | 5.27 | Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease. ( Allman-Farinelli, M; Carey, S; Cvejic, E; McCaughan, GW; Shackel, NA; Strasser, SI; Vidot, H, 2018) |
| "Ursodeoxycholic acid administration has been reported to improve cholestasis and inflammatory activity in primary biliary cirrhosis and, in an uncontrolled study, also in young adults with cystic fibrosis (CF) and chronic cholestasis." | 5.07 | Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. ( Angelico, M; Antonelli, M; Bertasi, S; De Santis, A; Diamanti, S; Goffredo, F; Martino, F; Merli, M; Quattrucci, S; Servi, R, 1994) |
| "This study was undertaken to clarify the effects of taurine on liver injury in rats with severe acute pancreatitis (SAP)." | 3.78 | Taurine attenuates liver injury by downregulating phosphorylated p38 MAPK of Kupffer cells in rats with severe acute pancreatitis. ( Chen, Y; Gong, J; Huang, Q; Li, J; Liu, Z; Wei, S; You, H, 2012) |
| "NorUDCA (24-norursodeoxycholic acid), the C₂₃-homolog of ursodeoxycholic acid (UDCA), showed remarkable therapeutic effects in cholestatic Mdr2 (Abcb4) (multidrug resistance protein 2/ATP-binding cassette b4) knockout mice with sclerosing/fibrosing cholangitis." | 3.76 | Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. ( Beuers, U; Denk, GU; Ferdinandusse, S; Fickert, P; Fuchsbichler, A; Hofmann, AF; Invernizzi, P; Kulik, W; Maitz, S; Rust, C; Trauner, M; Wimmer, R, 2010) |
| " Hepatotoxic compounds such as CCl4, galactosamine and thioacetamide that cause hepatic necrosis and compounds such as hydrazine and ethionine that cause fatty liver all result in elevated urinary taurine levels in rats." | 3.69 | Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. ( Timbrell, JA; Waterfield, CJ, 1996) |
| "The hydrophilic bile acid ursodeoxycholic acid (UDCA) has recently been shown to improve indexes of liver function in adult patients with various liver diseases." | 3.68 | Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. ( Colombo, C; Crosignani, A; Curcio, L; Giunta, A; Podda, M; Roda, A; Ronchi, M; Setchell, KD, 1990) |
| "The etiology of the severe hepatic dysfunction associated with total parenteral nutrition (TPN) remains unknown, but recent studies suggest that taurine deficiency may be associated with the development of cholestasis in experimental animals." | 3.67 | Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition. ( Betts, JM; Cooper, A; Pereira, GR; Ziegler, MM, 1984) |
| "Taurine is a fundamental mediator of homeostasis that exerts multiple roles to confer protection against oxidant stress." | 2.72 | Protective role of taurine against oxidative stress (Review). ( Adamaki, M; Baliou, S; Christodoulou, I; Ioannou, P; Kyriakopoulos, AM; Panayiotidis, MI; Pappa, A; Spandidos, DA; Zoumpourlis, V, 2021) |
| "Treatment with taurine was followed by a significant increase in serum prealbumin levels (P = ." | 2.68 | Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. ( Battezzati, PM; Bettinardi, N; Colombo, C; Giunta, A; Podda, M, 1996) |
| "Taurine treatment seems to be a useful agent for CYP2E1-related liver diseases with predominant damages in the PC region." | 2.50 | Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine. ( Matsuzaki, Y; Miyazaki, T, 2014) |
| "Taurine in diabetes has an age old story; taurine is involved in the development and protection of insulin apparatus." | 2.44 | Taurine-diabetes interaction: from involvement to protection. ( Gupta, RC; Kim, SJ; Lee, HW, 2007) |
| "Taurine has demonstrated promising actions in vitro, and as a result clinical trials have begun to investigate its effects on various diseases." | 2.43 | Is taurine a functional nutrient? ( Bouckenooghe, T; Remacle, C; Reusens, B, 2006) |
| " Treating mice with taurine at either dosing regimens, pre- or post-aluminum administration alleviated aluminum oxidative damaging effects." | 1.37 | Prophylactic and therapeutic effects of taurine against aluminum-induced acute hepatotoxicity in mice. ( Abdel-Moneim, AM; Al-Kahtani, MA; El-Sayed, WM, 2011) |
| "Taurine plays a protective role against free radicals and toxins in various cells and tissues." | 1.35 | The protective effect of taurine against hepatic damage in a model of liver disease and hepatic stellate cells. ( Bouscarel, B; Honda, A; Ikegami, T; Matsuzaki, Y; Miyazaki, T, 2009) |
| "Ischemia/reperfusion injury is mediated by various mechanisms." | 1.35 | Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury. ( Backhaus, J; Büchler, MW; Flechtenmacher, C; Gebhard, MM; Kincius, M; Liang, R; Schemmer, P; Schindler, G; Zorn, M, 2009) |
| "Taurine or betaine pretreatment in lipopolysaccharide-injected rats caused significant decreases in plasma transaminase activities and hepatic malondialdehyde and DC levels, and significant increases in glutathione and alpha-tocopherol (not betaine) levels without changing ascorbic acid levels and SOD and glutathione peroxidase activities in the liver." | 1.33 | The effect of taurine or betaine pretreatment on hepatotoxicity and prooxidant status induced by lipopolysaccharide treatment in the liver of rats. ( Aykaç-Toker, G; Balkan, J; Doğru-Abbasoğlu, S; Parldar, FH; Uysal, M, 2005) |
| " The contributions of the metabolites to the separation of control from dosed liver tissues varied depending on the type of spectral editing method used." | 1.32 | Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues. ( Antti, H; Beckonert, O; Bollard, ME; Ebbels, TM; Holmes, E; Keun, H; Lindon, JC; Nicholson, JK; Tang, H; Wang, Y, 2003) |
| "Taurine (200 mg/kg) was given 12 h before, at the time of, and 1 or 2 h after acetaminophen injection." | 1.31 | Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. ( Bouchier-Hayes, D; Kay, E; Redmond, HP; Wang, JH; Waters, E; Wu, QD, 2001) |
| " Light microscopic examination of sections of the liver taken 5 weeks after dosing of CCl4 showed hydropic degeneration of hepatocytes around the central veins and lipid vacuolation in mid-zonal and some periportal hepatocytes." | 1.29 | Abnormal expressions of hepatocellular proteins and extracellular matrix in CCL4-induced liver injury in rats. ( Chen, L; Yang, X; Zhong, X; Zhou, J, 1996) |
| " The peak elevation in urinary taurine occurred within the first 48 h after dosing but there was still significant taurinuria 72 and 96 h after the intermediate dose (1 ml." | 1.28 | Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats. ( Scales, MD; Timbrell, JA; Turton, JA; Waterfield, CJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (26.92) | 18.7374 |
| 1990's | 10 (19.23) | 18.2507 |
| 2000's | 13 (25.00) | 29.6817 |
| 2010's | 8 (15.38) | 24.3611 |
| 2020's | 7 (13.46) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T | 1 |
| Zhou, K | 1 |
| Sun, T | 1 |
| Sang, C | 1 |
| Jia, W | 1 |
| Xie, G | 1 |
| Claeys, W | 1 |
| Van Hoecke, L | 1 |
| Geerts, A | 1 |
| Van Vlierberghe, H | 1 |
| Lefere, S | 1 |
| Van Imschoot, G | 1 |
| Van Wonterghem, E | 1 |
| Ghesquière, B | 1 |
| Vandenbroucke, RE | 1 |
| Van Steenkiste, C | 1 |
| Tabori, H | 1 |
| Schneider, J | 1 |
| Lüth, S | 1 |
| Zagoya, C | 1 |
| Barucha, A | 1 |
| Lehmann, T | 1 |
| Kauf, E | 1 |
| Barth, A | 1 |
| Mainz, JG | 1 |
| Qiu, S | 1 |
| Li, X | 1 |
| Zhang, J | 1 |
| Shi, P | 1 |
| Cao, Y | 1 |
| Zhuang, Y | 1 |
| Tong, L | 1 |
| Wan, S | 1 |
| Yang, J | 1 |
| Mamtawla, G | 1 |
| Zhang, L | 1 |
| Gao, X | 1 |
| Wang, X | 1 |
| Xu, D | 1 |
| Liao, S | 1 |
| Lv, Y | 1 |
| Wang, J | 1 |
| Kong, L | 1 |
| Baliou, S | 1 |
| Adamaki, M | 1 |
| Ioannou, P | 1 |
| Pappa, A | 1 |
| Panayiotidis, MI | 1 |
| Spandidos, DA | 1 |
| Christodoulou, I | 1 |
| Kyriakopoulos, AM | 1 |
| Zoumpourlis, V | 1 |
| Merras-Salmio, L | 1 |
| Mutanen, A | 1 |
| Ylinen, E | 1 |
| Rintala, R | 1 |
| Koivusalo, A | 1 |
| Pakarinen, MP | 1 |
| Vidot, H | 1 |
| Cvejic, E | 1 |
| Carey, S | 1 |
| Strasser, SI | 1 |
| McCaughan, GW | 1 |
| Allman-Farinelli, M | 1 |
| Shackel, NA | 1 |
| Hernández-Sánchez, A | 1 |
| Tejada-González, P | 1 |
| Arteta-Jiménez, M | 1 |
| Miyazaki, T | 2 |
| Bouscarel, B | 1 |
| Ikegami, T | 1 |
| Honda, A | 1 |
| Matsuzaki, Y | 2 |
| Schindler, G | 1 |
| Kincius, M | 1 |
| Liang, R | 1 |
| Backhaus, J | 1 |
| Zorn, M | 1 |
| Flechtenmacher, C | 1 |
| Gebhard, MM | 1 |
| Büchler, MW | 1 |
| Schemmer, P | 1 |
| Acharya, M | 1 |
| Lau-Cam, CA | 1 |
| Denk, GU | 1 |
| Maitz, S | 1 |
| Wimmer, R | 1 |
| Rust, C | 1 |
| Invernizzi, P | 1 |
| Ferdinandusse, S | 1 |
| Kulik, W | 1 |
| Fuchsbichler, A | 1 |
| Fickert, P | 1 |
| Trauner, M | 1 |
| Hofmann, AF | 1 |
| Beuers, U | 1 |
| El-Sayed, WM | 1 |
| Al-Kahtani, MA | 1 |
| Abdel-Moneim, AM | 1 |
| Wei, S | 1 |
| Huang, Q | 1 |
| Li, J | 1 |
| Liu, Z | 1 |
| You, H | 1 |
| Chen, Y | 1 |
| Gong, J | 1 |
| TURNER, FP | 1 |
| BRUM, VC | 1 |
| PAQUETTE, WW | 1 |
| WELDEN, RB | 1 |
| Wang, Y | 1 |
| Bollard, ME | 1 |
| Keun, H | 1 |
| Antti, H | 1 |
| Beckonert, O | 1 |
| Ebbels, TM | 1 |
| Lindon, JC | 2 |
| Holmes, E | 1 |
| Tang, H | 2 |
| Nicholson, JK | 2 |
| Braumann, C | 1 |
| Stuhldreier, B | 1 |
| Bobrich, E | 1 |
| Menenakos, C | 1 |
| Rogalla, S | 1 |
| Jacobi, CA | 1 |
| Balkan, J | 1 |
| Parldar, FH | 1 |
| Doğru-Abbasoğlu, S | 1 |
| Aykaç-Toker, G | 1 |
| Uysal, M | 1 |
| Zwingmann, C | 1 |
| Bilodeau, M | 1 |
| Yap, IK | 1 |
| Clayton, TA | 1 |
| Everett, JR | 1 |
| Hanton, G | 1 |
| Provost, JP | 1 |
| Le Net, JL | 1 |
| Charuel, C | 1 |
| Bouckenooghe, T | 1 |
| Remacle, C | 1 |
| Reusens, B | 1 |
| Warskulat, U | 2 |
| Borsch, E | 1 |
| Reinehr, R | 1 |
| Heller-Stilb, B | 2 |
| Roth, C | 1 |
| Witt, M | 1 |
| Häussinger, D | 2 |
| Oermann, E | 1 |
| Zilles, K | 1 |
| Haas, H | 1 |
| Lang, F | 1 |
| Kim, SJ | 1 |
| Gupta, RC | 1 |
| Lee, HW | 1 |
| Linnet, K | 1 |
| Andersen, JR | 1 |
| Cooper, A | 1 |
| Betts, JM | 1 |
| Pereira, GR | 1 |
| Ziegler, MM | 1 |
| Kamada, S | 1 |
| Maeda, M | 1 |
| Tsuji, A | 1 |
| Nakashima, T | 1 |
| Taniko, T | 1 |
| Kuriyama, K | 1 |
| Benjamin, LE | 1 |
| Steele, RD | 1 |
| Merli, M | 1 |
| Bertasi, S | 1 |
| Servi, R | 1 |
| Diamanti, S | 1 |
| Martino, F | 1 |
| De Santis, A | 1 |
| Goffredo, F | 1 |
| Quattrucci, S | 1 |
| Antonelli, M | 1 |
| Angelico, M | 1 |
| Smith, CA | 1 |
| Donovan, JM | 1 |
| Yousef, IM | 1 |
| Carey, MC | 1 |
| O'Connor, PJ | 1 |
| Southern, KW | 1 |
| Bowler, IM | 1 |
| Irving, HC | 1 |
| Robinson, PJ | 1 |
| Littlewood, JM | 1 |
| Colombo, C | 2 |
| Battezzati, PM | 1 |
| Podda, M | 2 |
| Bettinardi, N | 1 |
| Giunta, A | 2 |
| Timbrell, JA | 2 |
| Waterfield, CJ | 2 |
| Zhou, J | 2 |
| Zhong, X | 1 |
| Chen, L | 1 |
| Yang, X | 1 |
| Waters, E | 1 |
| Wang, JH | 1 |
| Redmond, HP | 1 |
| Wu, QD | 1 |
| Kay, E | 1 |
| Bouchier-Hayes, D | 1 |
| Btaiche, IF | 1 |
| Khalidi, N | 1 |
| Westergaard, H | 1 |
| Bosman, DK | 1 |
| Deutz, NE | 1 |
| Maas, MA | 1 |
| van Eijk, HM | 1 |
| Smit, JJ | 1 |
| de Haan, JG | 1 |
| Chamuleau, RA | 1 |
| Turton, JA | 1 |
| Scales, MD | 1 |
| Setchell, KD | 1 |
| Crosignani, A | 1 |
| Roda, A | 1 |
| Curcio, L | 1 |
| Ronchi, M | 1 |
| Lawson, AM | 1 |
| Madigan, MJ | 1 |
| Shortland, D | 1 |
| Clayton, PT | 1 |
| Kendler, BS | 1 |
| Sugiyama, K | 1 |
| Okuyama, S | 1 |
| Imoto, M | 1 |
| Okumura, K | 1 |
| Takagi, K | 1 |
| Satake, T | 1 |
| Sherr, HP | 1 |
| Nair, PP | 1 |
| White, JJ | 1 |
| Banwell, JG | 1 |
| Lockwood, DH | 1 |
| Hardison, WG | 1 |
| Verzetti, G | 1 |
| Emanuelli, G | 1 |
| Montagnani, M | 1 |
| Neale, G | 1 |
| Lewis, B | 1 |
| Weaver, V | 1 |
| Panveliwalla, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants[NCT00711763] | 1 participants (Actual) | Observational | 2008-07-31 | Terminated (stopped due to failure to recruit more patients and lack of supporting personnel.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for taurine and Liver Dysfunction
| Article | Year |
|---|---|
Protective role of taurine against oxidative stress (Review).
Topics: Animals; Antioxidants; Heart Diseases; Homeostasis; Humans; Liver Diseases; Muscular Diseases; Nervo | 2021 |
Aluminium in parenteral nutrition: a systematic review.
Topics: Aluminum; Alzheimer Disease; Bone Diseases, Metabolic; Deferoxamine; Dyslipidemias; Humans; Iron; Ke | 2013 |
Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine.
Topics: Animals; Cytochrome P-450 CYP2E1; Humans; Liver; Liver Diseases; Oxidative Stress; Taurine; Xenobiot | 2014 |
Is taurine a functional nutrient?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Immunologic Factors; Liver Diseases; Nervous System Dise | 2006 |
Phenotype of the taurine transporter knockout mouse.
Topics: Animals; Brain; Ear, Inner; Female; Kidney; Liver; Liver Diseases; Male; Membrane Glycoproteins; Mem | 2007 |
Taurine-diabetes interaction: from involvement to protection.
Topics: Animals; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes | 2007 |
Parenteral nutrition-associated liver complications in children.
Topics: Alkaline Phosphatase; Anti-Bacterial Agents; Bilirubin; Carnitine; Child; Cholestasis; gamma-Glutamy | 2002 |
Taurine: an overview of its role in preventive medicine.
Topics: Animals; Cardiovascular Diseases; Cystic Fibrosis; Epilepsy; Humans; Infant, Newborn; Liver Diseases | 1989 |
Bile salts and the liver.
Topics: Acute Kidney Injury; Animals; Bile Acids and Salts; Biological Transport, Active; Cholesterol; Feedb | 1972 |
3 trials available for taurine and Liver Dysfunction
| Article | Year |
|---|---|
Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease.
Topics: Administration, Oral; Australia; Chronic Disease; Dietary Supplements; Female; Humans; Liver Disease | 2018 |
Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
Topics: Absorption; Adolescent; Adult; Bile Acids and Salts; Child; Cross-Over Studies; Cystic Fibrosis; Die | 1994 |
Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Topics: 5'-Nucleotidase; Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; D | 1996 |
40 other studies available for taurine and Liver Dysfunction
| Article | Year |
|---|---|
Altered bile acid glycine : taurine ratio in the progression of chronic liver disease.
Topics: Bile Acids and Salts; Case-Control Studies; Chronic Disease; Disease Progression; Female; Glycine; H | 2022 |
A mouse model of hepatic encephalopathy: bile duct ligation induces brain ammonia overload, glial cell activation and neuroinflammation.
Topics: Ammonia; Animals; Bile Acids and Salts; Bile Ducts; Brain; Choline; Disease Models, Animal; Glutamin | 2022 |
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
Topics: Bile Acids and Salts; Cholic Acid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2022 |
Neutrophil membrane-coated taurine nanoparticles protect against hepatic ischemia-reperfusion injury.
Topics: Glutathione; Humans; Interleukin-6; Liver; Liver Diseases; Neutrophils; Oxidative Stress; Reperfusio | 2023 |
Differential Metabolomic Analysis of Liver Tissues from Rat Models of Parenteral Nutrition-Associated Liver Disease.
Topics: Acetyl Coenzyme A; Animals; Bile Acids and Salts; Choline; Enteral Nutrition; Fatty Acids, Unsaturat | 2020 |
NMR-based metabolomics approach reveals effects of antioxidant nutrients in sepsis-induced changes in rat liver injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Disease Models, Animal; Glutathione; Liver Diseases; Magnetic | 2020 |
Pediatric Intestinal Failure: The Key Outcomes for the First 100 Patients Treated in a National Tertiary Referral Center During 1984-2017.
Topics: Catheter-Related Infections; Child; Child, Preschool; Digestive System Surgical Procedures; Female; | 2018 |
The protective effect of taurine against hepatic damage in a model of liver disease and hepatic stellate cells.
Topics: Animals; Base Sequence; Disease Models, Animal; DNA Primers; Liver Diseases; Male; Oxidative Stress; | 2009 |
Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury.
Topics: Alanine; Animals; Arginine; Chemotaxis, Leukocyte; Clinical Enzyme Tests; Drug Therapy, Combination; | 2009 |
Comparison of the protective actions of N-acetylcysteine, hypotaurine and taurine against acetaminophen-induced hepatotoxicity in the rat.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Animals; Antioxidants; Chemical and Drug In | 2010 |
Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Topics: Animals; Apoptosis; Bile; Bile Acids and Salts; Carcinoma, Hepatocellular; Cholangitis; Cholestasis; | 2010 |
Prophylactic and therapeutic effects of taurine against aluminum-induced acute hepatotoxicity in mice.
Topics: Aluminum; Animals; Liver; Liver Diseases; Mice; Microscopy, Electron, Transmission; Taurine | 2011 |
Taurine attenuates liver injury by downregulating phosphorylated p38 MAPK of Kupffer cells in rats with severe acute pancreatitis.
Topics: Alanine Transaminase; Amylases; Animals; Aspartate Aminotransferases; Down-Regulation; Interleukin-1 | 2012 |
THE URINARY EXCRETION OF FREE TAURINE IN ACUTE AND CHRONIC DISEASE, FOLLOWING SURGICAL TRAUMA, AND IN PATIENTS WITH ACUTE ALCOHOLISM.
Topics: Adrenal Cortex Hormones; Alcoholism; Biliary Tract; Biomedical Research; Cholecystitis; Cholelithias | 1964 |
Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues.
Topics: Alanine; Animals; Chemical and Drug Induced Liver Injury; Choline; Glucose; Glycogen; Hydrazines; Li | 2003 |
High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biopsy; Cell Division; Cell Line, Tumor; Chemical an | 2005 |
The effect of taurine or betaine pretreatment on hepatotoxicity and prooxidant status induced by lipopolysaccharide treatment in the liver of rats.
Topics: Animals; Antioxidants; Betaine; Chemical and Drug Induced Liver Injury; Lipopolysaccharides; Liver D | 2005 |
Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver.
Topics: Acetylcysteine; Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Citric Acid Cycle; Cy | 2006 |
An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate.
Topics: Animals; Blood Chemical Analysis; Chemical and Drug Induced Liver Injury; Creatine; Formic Acid Este | 2006 |
Taurine deficiency and apoptosis: findings from the taurine transporter knockout mouse.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; fas Receptor; Liver Diseases; Membrane Glycoprote | 2007 |
Differential diagnostic value in hepatobiliary disease of serum conjugated bile acid concentrations and some routine liver tests assessed by discriminant analysis.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Bile Acids and Salts; Bi | 1983 |
Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition.
Topics: Amino Acids; Cholestasis; Female; Humans; Infant, Newborn; Liver Diseases; Parenteral Nutrition; Par | 1984 |
Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene as a pre-labeling reagent.
Topics: Bile; Bile Acids and Salts; Chromatography, High Pressure Liquid; Fluorescent Dyes; Glycine; Humans; | 1983 |
Therapeutic effect of taurine administration on carbon tetrachloride-induced hepatic injury.
Topics: Animals; Antioxidants; Calcium; Carbon Tetrachloride Poisoning; Electron Transport; Lipid Peroxides; | 1982 |
Effect of portacaval shunt on sulfur amino acid metabolism in rats.
Topics: Amino Acids, Sulfur; Animals; Disease Models, Animal; Glutathione; Liver Diseases; Male; Oxidation-R | 1981 |
Changes and challenges in feline nutrition.
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Cat Diseases; Cats; Diabetes Melli | 1993 |
Pan-sulfation of bile salts markedly increases hydrophilicity and essentially abolishes self- and hetero-association with lecithin.
Topics: Bile Acids and Salts; Cholestasis; Glycine; Humans; Hydrogen-Ion Concentration; Liver Diseases; Memb | 1993 |
The role of hepatobiliary scintigraphy in cystic fibrosis.
Topics: Adolescent; Adult; Biliary Tract; Child; Child, Preschool; Cystic Fibrosis; Female; Follow-Up Studie | 1996 |
Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro.
Topics: Animals; Biomarkers; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Cells, Cultured; Clenbute | 1996 |
Abnormal expressions of hepatocellular proteins and extracellular matrix in CCL4-induced liver injury in rats.
Topics: Animals; Apoptosis; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Extracellular Matr | 1996 |
Role of taurine in preventing acetaminophen-induced hepatic injury in the rat.
Topics: Acetaminophen; Alanine Transaminase; Alkaline Phosphatase; Analgesics, Non-Narcotic; Animals; Apopto | 2001 |
Duodenal bile acid concentrations in fat malabsorption syndromes.
Topics: Adult; Bile Acids and Salts; Biliary Tract Diseases; Celiac Disease; Duodenum; Female; Food; Glycine | 1977 |
Amino acid release from cerebral cortex in experimental acute liver failure, studied by in vivo cerebral cortex microdialysis.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Cerebral Cortex; Dialysis; gamma-Aminobutyric Ac | 1992 |
Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Carbon Tetrachloride; Chemic | 1991 |
Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Topics: Adolescent; Bile Acids and Salts; Child; Cystic Fibrosis; Deoxycholic Acid; Female; Humans; Liver Di | 1990 |
Rapid diagnosis of Zellweger syndrome and infantile Refsum's disease by fast atom bombardment--mass spectrometry of urine bile salts.
Topics: Bile Acids and Salts; Brain Diseases; Chemical Fractionation; Cholic Acids; Female; Gas Chromatograp | 1986 |
Clinical evaluation of serum 3 beta-hydroxy-5-cholenoic acid in hepatobiliary diseases.
Topics: 3-Hydroxysteroid Dehydrogenases; Bile Acids and Salts; Bilirubin; Cholestasis, Extrahepatic; Cholest | 1986 |
Bile acid metabolism and hepatic disease following small bowel bypass for obesity.
Topics: Adult; Bile; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholic Acids; Deoxycholic Acid; | 1974 |
[Therapy of hyperammonemia: effect of a preparation arginine pyrrolidonecarboxylate, taurine, vitamin B6 and citric acid].
Topics: Amino Acids; Ammonia; Arginine; Brain Diseases; Citrates; Drug Combinations; Hepatic Encephalopathy; | 1972 |
Serum bile acids in liver disease.
Topics: Adult; Aged; Bile Acids and Salts; Biliary Tract Diseases; Cholanes; Cholestasis; Colitis, Ulcerativ | 1971 |